Article ID Journal Published Year Pages File Type
6184703 Gynecologic Oncology 2016 6 Pages PDF
Abstract
The MTD of veliparib combined with CD is 80 mg p.o. b.i.d. in women with recurrent, platinum-sensitive ovarian cancer. With bevacizumab, DLTs were noted in 9 out of 12 patients. Lower doses of veliparib will need to be considered when given in combination with platinum-based therapies.
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Authors
, , , , , , , , ,